SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-19-077344
Filing Date
2019-12-31
Accepted
2019-12-31 16:45:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a19-28291_3sc13da.htm SC 13D/A 43824
2 EX-7.07 a19-28291_3ex7d07.htm EX-7.07 48605
  Complete submission text file 0001104659-19-077344.txt   94229
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filed by) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D/A

Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Subject) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-88883 | Film No.: 191319866
SIC: 2834 Pharmaceutical Preparations